MC
VRDN icon

Maverick Capital’s Viridian Therapeutics VRDN Stock Holding History

Maverick Capital’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,212,701
Closed -$47.8M – 259
2025
Q3 		$47.8M Sell
2,212,701
-44,309
-2% -$799K 0.64% 42
2025
Q2 		$31.6M Buy
2,257,010
+195,736
+9% +$2.66M 0.47% 46
2025
Q1 		$27.8M Buy
2,061,274
+7,368
+0.4% +$126K 0.49% 50
2024
Q4 		$39.4M Buy
2,053,906
+56,753
+3% +$1.23M 0.71% 43
2024
Q3 		$45.4M Sell
1,997,153
-1,310,792
-40% -$21.4M 0.89% 37
2024
Q2 		$43M Buy
3,307,945
+615,531
+23% +$8.52M 0.82% 39
2024
Q1 		$47.1M Buy
2,692,414
+366,573
+16% +$7.11M 0.89% 37
2023
Q4 		$50.7M Buy
+2,325,841
New +$36.7M 1.02% 32

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Maverick Capital's VRDN Position: Q4 2025 in Review

Maverick Capital sold out of Viridian Therapeutics (VRDN) in Q4 2025, closing a stake of 2,212,701 shares — an estimated $47.8M sold.

Maverick Capital first reported a position in VRDN in Q4 2023 and held it in 8 quarters. The position peaked at $50.7M in Q4 2023. 229 funds tracked by Wall St. Rank hold VRDN as of Q4 2025.

  • Maverick Capital reported no remaining Viridian Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Maverick Capital sold 2,212,701 Viridian Therapeutics shares in Q4 2025, an estimated $47.8M.
  • Maverick Capital first reported a position in Viridian Therapeutics in Q4 2023 and held it in 8 quarters.
  • Maverick Capital's Viridian Therapeutics position peaked at $50.7M in Q4 2023.
  • 229 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q4 2025.

Based on Maverick Capital's 13F filing for Q4 2025, filed 13 Feb 2026.